

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/803,146	
	Filing Date	March 17, 2004	
	First Named Inventor	N J Britten et al.	
	Art Unit	1614	
	Examiner Name	Not yet available	
Total Number of Pages in This Submission	1	Attorney Docket Number	01559.US1


ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	A return-receipt postcard is enclosed. References Remarks
<input checked="" type="checkbox"/> Identify below: A return-receipt postcard is enclosed. References			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Pharmacia & Upjohn Company, John H. Engelmann (28,075)
Signature	
Date	MAY 5, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Julie K. Lyons
Signature	
Date	May 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>			Atty. Docket No. 01559.US1		Serial No. 10/803,146			
			Applicants N. J. Britten, et al.					
			Filing Date 3/17/2004		1614			
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AY	WO 02/22107 A2	March 21, 2002	WIPO	A61K	9/00		
	AZ	WO 02/06865 A2	Jan. 24, 2002	WIPO	G02B	6/00		
	BA	WO 01/60409 A1	Aug. 23, 2001	WIPO	A61K	47/02		
	BB	WO 00/24719	May 4, 2000	WIPO	C07D	237/14		
	BC	WO 99/20259 A2 A3	April 29, 1999	WIPO	A61K	31/00		
	BD	WO 98/03484	Jan. 29, 1998	WIPO	C07D	213/34		
	BE	BG 1 181 527	Feb 18, 1970	British	A61K	27/00		
	BF	EP 0 222 712 A2 B1	Nov. 4, 1986	Europe	A61K	47/00		
	BG	EP 0 863 134	Sept. 9, 1998	Europe	C07D	317/24		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	BH	Estrada (March 1997), Infect. in Med. 14(3), 239-244						
	BI	Gao et al. (1995) in Pharmaceutical Research 12(6), 857-863, "Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation"						
	BJ	Gao et al. (1995) in Pharmaceutical Research 12(6), 864-868, "Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vivo evaluation"						
	BK	The Merck Manual, "Acute Otitis Media", 17 th edition (1999), Section 7, Chapter 84						
	BL	The Merck Manual, "Chronic Otitis Media", 17 th edition (1999), Section 7, Chapter 84						
	BM	The Merck Manual, "Secretory Otitis Media", 17 th edition (1999), Section 7, Chapter 84						
	BN	National Formulary, 19 th ed. (NF 19), "Microcrystalline Wax", 2536-7						
Examiner			Date Considered					



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Atty. Docket No.

01559.US1

Serial No.

10/803,146

Applicants N. J. Britten, et al.

Filing Date 3/17/2004

1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	6,509,327	Jan. 21, 2003	Cagle et al.	514	171	
	AB	6,440,964	Aug. 27, 2002	Cagle et al.	514	230.05	
	AC	6,395,746	May 28, 2002	Cagle et al.	514	300	
	AD	6,329,526	Dec. 11, 2001	Adams et al.	546	274.1	
	AE	6,307,047	Oct. 23, 2001	Black et al.	544	240	
	AF	5,965,549	Oct. 12, 1999	Purwar et al.	514	177	
	AG	5,932,598	Aug. 3, 1999	Talley et al.	514	341	
	AH	5,892,053	April 6, 1999	Zhi et al.	548	377.1	
	AI	5,756,529	May 26, 1999	Isakson et al.	514	406	
	AJ	5,679,665	Oct. 21, 1997	Bergamini et al.	514	171	
	AK	5,633,272	May 27, 1997	Talley et al.	514	378	
	AL	5,474,995	Dec. 12, 1995	Ducharme et al.	514	241	
	AM	5,466,823	Nov. 14, 1995	Talley et al.	548	377.1	
	AN	3,636,194	Jan. 18, 1972	Parizeau	424	115	
	AO	2002/0142999	Oct. 3, 2002	Cagle et al.	514	171	
	AP	2002/0076383	June 20, 2002	Mautone	424	45	
	AQ	2002/0064503	May 30, 2002	Mautone	424	45	
	AR	2002/0044920	April 18, 2002	Rahman et al.	424	85.1	
	AS	2002/0032228	March 14, 2002	Peterson et al.	514	396	
	AT	2002/0013318	Jan. 31, 2002	Black et al.	514	248	
	AU	2002/0010146	Jan. 24, 2002	Garvey et al.	514	44	
	AV	2001/0053764	Dec. 20, 2001	Sims et al.	514	12	
	AW	2001/0049366	Dec. 6, 2001	Singh et al.	514	171	
	AX	2001/0041726	Nov. 15, 2001	Bandarage et al.	514	361	